Sign up to save your podcasts
Or
Share Psychedelics in Massachusetts: The future of MDMA-assisted therapy for PTSD
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Psychedelics in Massachusetts: The future of MDMA-assisted therapy for PTSD
The U.S. Food and Drug Administration is reviewing MDMA-assisted therapy for post-traumatic stress disorder, which could become the first psychedelic-assisted therapy as early as August.
Today, The Common presents the final episode of our three-part series looking at the past, present and future of psychedelics in Massachusetts as a potential ballot question that could lead to the decriminalization of natural psychedelic substances in Massachusetts.
Rick Doblin, founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), is featured in today's conversation. He has led efforts to bring psychedelics back into mainstream medicine, in part by organizing clinical drug trials to get MDMA-assisted therapy for PTSD approved by the FDA.
Greater Boston’s weekly podcast where news and culture meet.
View all episodes
By WBUR
4.7
8080 ratings
The U.S. Food and Drug Administration is reviewing MDMA-assisted therapy for post-traumatic stress disorder, which could become the first psychedelic-assisted therapy as early as August.
Today, The Common presents the final episode of our three-part series looking at the past, present and future of psychedelics in Massachusetts as a potential ballot question that could lead to the decriminalization of natural psychedelic substances in Massachusetts.
Rick Doblin, founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), is featured in today's conversation. He has led efforts to bring psychedelics back into mainstream medicine, in part by organizing clinical drug trials to get MDMA-assisted therapy for PTSD approved by the FDA.
Greater Boston’s weekly podcast where news and culture meet.